Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03192410
Other study ID # Alpha Omega Cohort
Secondary ID
Status Active, not recruiting
Phase N/A
First received June 10, 2017
Last updated June 15, 2017
Start date April 2002
Est. completion date January 2040

Study information

Verified date June 2017
Source Wageningen University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The Alpha Omega Cohort is a prospective study of 4,837 state-of-the-art drug-treated Dutch patients aged 60-80 years who had a clinically diagnosed myocardial infarction up to 10 years before enrolment. During the first 40 months of follow-up, patients took part in an experimental study of low doses n-3 fatty acids (Alpha Omega Trial, ClinicalTrials.gov NCT00127452). At baseline (2002-2006), data on medical history, medication use, diet, lifestyle and other factors were collected by means of questionnaires. Patients were physically examined by trained research nurses and blood samples were obtained. Follow-up for vital status and cause-specific mortality is ongoing. The trial was approved by a central medical ethics committee (Haga Hospital, The Hague, The Netherlands) and all patients provided written informed consent.


Description:

Details are reported in publications.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 4837
Est. completion date January 2040
Est. primary completion date January 2040
Accepts healthy volunteers No
Gender All
Age group 60 Years to 80 Years
Eligibility The Alpha Omega Cohort is a prospective cohort study. The cohort originated from the Alpha Omega Trial, a 40-month intervention study of low doses of n-3 fatty acids (in margarine spreads) and cardiovascular events (NCT00127452). The in/exclusion criteria were defined for the Alpha Omega Trial.

Inclusion criteria:

- Men and women

- Aged 60 through 80 y

- Verified clinically diagnosed myocardial infarction up to 10 y before entry into the study

- Written informed consent

Exclusion criteria:

- Living in a nursing home or other institution

- Participation in another scientific study

- Habitual margarine intake < 10 g per day

- Habitual fish intake > 150 g per day

- Habitual alcohol intake > 6 drinks per day

- Use of fish oil capsules or other supplements containing omega-3 fatty acids

- Presence of cancer with < 1 y of life expectancy

- Cognitive impairment, as indicated by the Mini Mental State Examination (score <= 21)

- Unintended weight loss > 5 kg in the past year

- Lack of facilities for cooled margarine storage at home

- Inability or unwillingness to comply with study procedures

Study Design


Intervention

Behavioral:
Dietary intake
Intake of nutrients, foods, food groups, beverages; dietary patterns.
Lifestyle factors
Physical activity; smoking; alcohol use; educational level.
Biological:
Blood biomarkers
Biomarkers of dietary intake (e.g. fatty acids); biomarkers of disease.
Health
Current health status; medical history; medication use; self-rated health; risk factors for disease (e.g. body mass index, blood pressure, blood lipids, glucose)
Genetic:
DNA
SNPs (GWAS)
Biological:
Mental well-being
Cognitive function; dispositional optimism; depression.

Locations

Country Name City State
Netherlands Wageningen University, Division of Human Nutrition Wageningen

Sponsors (1)

Lead Sponsor Collaborator
Wageningen University

Country where clinical trial is conducted

Netherlands, 

References & Publications (6)

Geleijnse JM, Giltay EJ, Schouten EG, de Goede J, Oude Griep LM, Teitsma-Jansen AM, Katan MB, Kromhout D; Alpha Omega Trial Group. Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. Am Heart J. 2010 Apr;159(4):539-546.e2. doi: 10.1016/j.ahj.2009.12.033. — View Citation

Hoogeveen EK, Geleijnse JM, Kromhout D, Stijnen T, Gemen EF, Kusters R, Giltay EJ. Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clin J Am Soc Nephrol. 2014 Oct 7;9(10):1676-83. doi: 10.2215/CJN.10441 — View Citation

Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010 Nov 18;363(21):2015-26. doi: 10.1056/NEJMoa1003603. Epub 2010 Aug 28. — View Citation

Sijtsma FP, Soedamah-Muthu SS, de Goede J, Oude Griep LM, Geleijnse JM, Giltay EJ, de Boer MJ, Jacobs DR Jr, Kromhout D. Healthy eating and lower mortality risk in a large cohort of cardiac patients who received state-of-the-art drug treatment. Am J Clin — View Citation

Soedamah-Muthu SS, Geleijnse JM, Giltay EJ, de Goede J, Oude Griep LM, Waterham E, Teitsma-Jansen AM, Mulder BJ, de Boer MJ, Deckers JW, Zock PL, Kromhout D; for the Alpha Omega Trial Group . Levels and trends in cardiovascular risk factors and drug treat — View Citation

Soedamah-Muthu SS, Geleijnse JM, Giltay EJ, Kromhout D; Alpha Omega Trial Group. Cardiovascular risk factor management of myocardial infarction patients with and without diabetes in the Netherlands between 2002 and 2006: a cross-sectional analysis of base — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Depression Score on 15-item Geriatric Depression Scale After 40 months of follow-up
Other Dispositional optimism Scores on a 4-item questionnaire and the (revised) Life Orientation Test (LOT-R) After 40 months of follow-up
Other Body weight Change in body weight, assessed by trained research nurses From entry into the study (baseline: 2002-2006) until November 2009
Other Blood pressure Change in office blood pressure, assessed by trained research nurses From entry into the study (baseline: 2002-2006) until November 2009
Other Blood lipids Change in non-fasting serum total, LDL and HDL cholesterol, assessed by standard laboratory methods From entry into the study (baseline: 2002-2006) until November 2009
Other Glucose metabolism Change in non-fasting plasma glucose, insulin and HbA1C, assessed by standard laboratory methods From entry into the study (baseline: 2002-2006) until November 2009
Other DNA genotype DNA genotype, assessed by Global Screening Array (Illumina, Inc.) At baseline (2002-2006)
Other Biochemical markers of Inflammation Change in blood biomarkers of inflammation, assessed by MesoScale assays From entry into the study (baseline: 2002-2006) until November 2009
Other Biochemical markers of endothelial function Change in blood biomarkers of endothelial function, assessed by MesoScale assays From entry into the study (baseline: 2002-2006) until November 2009
Other Biomarkers of cardiac function Change in blood biomarkers of cardiac function (e.g, NT-proBNP, troponin), assessed by chemiluminescence From entry into the study (baseline: 2002-2006) until November 2009
Other Biomarkers of kidney function Change in blood biomarkers of kidney function, assessed by immunoassay From entry into the study (baseline: 2002-2006) until November 2009
Other Prostate-specific antigen (PSA) Change in blood total PSA concentration, assessed by immunometric assay From entry into the study (baseline: 2002-2006) until November 2009
Other Testosterone Change in serum testosterone concentration, assessed by immunoassay From entry into the study (baseline: 2002-2006) until November 2009
Other Circulating fatty acids Change in concentration of fatty acids (percent weight) in plasma cholesteryl esters From entry into the study (baseline: 2002-2006) until November 2009
Primary Cardiovascular mortality Death from cardiovascular disease, obtained from causes of death register of Statistics Netherlands From entry into the study (baseline: 2002-2006) through study completion
Primary All-cause mortality Vital status obtained from municipal population registers in the Netherlands From entry into the study (baseline: 2002-2006) through study completion
Primary Major cardiovascular events Incidence of fatal and nonfatal cardiovascular events and hospitalisations for cardiac interventions, based on verified information from GP records, hospital records and mortality registers From entry into the study (baseline: 2002-2006) until November 2009
Secondary Coronary heart disease Incidence of fatal and non-fatal coronary heart disease, based on verified information from GP records, hospital records and mortality registers From entry into the study (baseline: 2002-2006) through study completion
Secondary Stroke Incidence of fatal and non-fatal stroke, based on verified information from GP records, hospital records and mortality registers From entry into the study (baseline: 2002-2006) through study completion
Secondary Non-cardiovascular mortality Death from cancer or other non-cardiovascular causes, obtained from causes of death register of Statistics Netherlands From entry into the study (baseline: 2002-2006) through study completion
Secondary Type 2 diabetes Incidence of type 2 diabetes, on basis of self-reported physician diagnosis, use of antidiabetic drugs, or elevated blood glucose From entry into the study (baseline: 2002-2006) until November 2009
Secondary Kidney function Change in serum cystatin C-based estimated glomerular filtration rate From entry into the study (baseline: 2002-2006) until November 2009
Secondary Cognitive function Change in global cognitive function, based on Mini Mental State Examination (MMSE) score From entry into the study (baseline: 2002-2006) until November 2009
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)